5,50 €
0,77 %vorgestern
L&S, 23. Februar, 22:54 Uhr
ISIN
CA05156V1022
Symbol
AUPH
Berichte
Sektor
Industrie

Aurinia Pharmaceuticals Inc. Aktie News

Negativ
Invezz
10 Tage alt
U.S.-listed shares of Aurinia Pharmaceuticals (AUPH.O) witnessed a significant downturn, plummeting 25% to $6 in pre-market trading. The pharmaceutical company announced the conclusion of its strategic review, initiated in June 2023, but failed to attract any formal offers, a report by Reuters said.
Neutral
Seeking Alpha
10 Tage alt
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript
Negativ
Reuters
10 Tage alt
Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thursday.
Neutral
Business Wire
10 Tage alt
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company's strategic review. This includes corporate actions designed to enhance shareholder value, including an exclusive focus on driving...
Negativ
Reuters
10 Tage alt
Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost cuts instead, people familiar with the matter said.
Neutral
Business Wire
20 Tage alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024.
Neutral
Business Wire
etwa 2 Monate alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results.
Neutral
Business Wire
2 Monate alt
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen